NCT04141176 (Spiri+) is a NA clinical trial of Spiri+ in Obstructive Sleep Apnea Syndrome, sponsored by Sleepinnov Technology.

Who is sponsoring NCT04141176?

NCT04141176 is sponsored by Sleepinnov Technology.

What drugs are being tested in NCT04141176?

Interventions in NCT04141176: Spiri+.

What condition does NCT04141176 study?

NCT04141176 studies Obstructive Sleep Apnea Syndrome.

Is NCT04141176 still recruiting?

NCT04141176 is currently completed. Last updated 25 August 2020.

Last reviewed 2020-08-25 · How we verify

NCT04141176: Spiri+

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Obstructive Sleep Apnea Syndrome: Evaluation of the Efficacy of Sleepinnov© (Spiri+) Continuous Positive Airway Pressure Device

Completed NA Last updated 25 August 2020

What this trial tests

NA trial testing Spiri+ in Obstructive Sleep Apnea Syndrome in 20 participants. Completed in 23 June 2020.

Timeline

16 November 2019

Primary endpoint
23 June 2020

23 June 2020

Quick facts

Lead sponsor	Sleepinnov Technology
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	16 November 2019
Primary completion	23 June 2020
Estimated completion	23 June 2020
Sites	1 location across France

Drugs / interventions tested

Spiri+

Conditions studied

Obstructive Sleep Apnea Syndrome — all drugs for Obstructive Sleep Apnea Syndrome →

Sponsor

Sleepinnov Technology

Who can join

18 and older, any sex, with Obstructive Sleep Apnea Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Continuous Positive Airway Pressure (CPAP) is the reference treatment of patients suffering from Obstructive Sleep Apnea Syndrome (OSAS).This device functions as a pneumatic stent that stabilizes the upper airway, prevents periodic collapses during sleep.The correction of abnormal respiratory events during sleep allows improvement of symptoms related to OSAS and restores quality of life.The purpose of this study is to validate the efficacy of a new CPAP brand developed by Sleepinnov©.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Obstructive Sleep Apnea Syndrome

Currently open trials in the same condition.

NCT05147649 — Functional Magnetic Resonance Imaging in Patients With Obstructive Sleep Apnea Syndrome · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04141176 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sleepinnov Technology
Last refreshed: 25 August 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04141176.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing